August 26, 2015
Ono Pharmaceutical and Novartis Pharma said on August 24 that their Alzheimer’s disease (AD) treatment rivastigmine (Ono: Rivastach Patch; Novartis: Exelon Patch) has obtained approval for a one-step titration regimen that makes it possible to reduce the period from initial...read more